ArticlePloS one2026
RETRACTED: SHP2 improved Late-onset fetal growth restriction via modulating ROS/BRD4/PI3K/YAP/PIGF signaling induced angiogenesis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Retraction · 2026-06-01Concerns/Issues about Article · Objections by Author(s) · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo look into the molecular processes and function of SHP2 in late-onset fetal growth restriction (LO-FGR).
methodsAn elaborate research technique included in vitro experiments and bioinformatics analysis. By identifying differentially expressed genes (DEGs) and enriched pathways linked to fetal growth restriction (FGR), the bioinformatics analysis of the GSE147776 dataset offered first insights into putative signaling networks, such as angiogenesis and oxidative stress. This bioinformatic information served as a guide for in vitro investigations using endothelial progenitor cells (EPCs) grown under circumstances similar to LO-FGR. EPCs were divided into six groups based on different drug treatments: NC group, Model group, Model + JQ-1 group, Model + JQ-1 + PHPS1 group, Model + JQ-1 + PHPS1 + 740Y-P group, and Model + JQ-1 + PHPS1 + 740Y-P + Verteporfin group. Using Western Blot analysis, the regulatory function of SHP2 in the ROS/BRD4 and PI3K/YAP/PIGF pathways was examined. We investigated the impact of SHP2 on the angiogenic potential of EPCs using tube formation assays and Western Blot analysis.Using Western Blot, colony formation assays, and flow cytometry to identify cell cycle progression and death, the mechanism by which SHP2 alleviates delayed fetal development limitation was investigated.
results207 DEGs were found to be considerably enriched in the Hedgehog and Hippo signaling pathways, according to a bioinformatics study of the FGR dataset GSE147776. It's interesting to note that SHP2 correlated positively with PI3K, CREB, and YAP and negatively with BRD4, NOX2, and P53. Under conditions akin to the in vivo LO-FGR environment, NOX4 and nuclear BRD4 protein expression dramatically rose, whereas p-SHP2, p-PI3K, nuclear YAP, Nrf2, PIGF, VEGF, HIF1α, OCT4, SOX2, and C-Myc protein expression greatly decreased. EPC proliferation was markedly reduced, the G2 phase of the cell cycle decreased, and apoptosis increased. After treatment with the BRD4 inhibitor JQ-1, the expression of NOX4 and nuclear BRD4 proteins significantly decreased, while the expression of p-SHP2, p-PI3K, nuclear YAP, Nrf2, PIGF, VEGF, HIF1α, OCT4, SOX2, and C-Myc proteins increased. EPC proliferation increased, the G2 phase of the cell cycle increased, and apoptosis decreased. When SHP2 was inhibited, NOX4 expression increased, while the expression of p-SHP2, p-PI3K, nuclear YAP, Nrf2, PIGF, VEGF, HIF1α, OCT4, SOX2, and C-Myc proteins decreased. EPC proliferation decreased, the G2 phase of the cell cycle decreased, and apoptosis increased.
conclusionSHP2 improves LO-FGR by regulating ROS/BRD4 and PI3K/YAP/PIGF-induced activation of endothelial progenitor cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.